Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Progressing tumors in man and mouse are often infiltrated by dendritic cells (DCs). Deficient antitumor immunity could be related to a lack of tumor-associated antigen (TAA) presentation by tumor-infiltrating DCs (TIDCs) or to a functional defect of TIDCs. Here we investigated the phenotype and function of TIDCs in transplantable and transgenic mouse tumor models. Although TIDCs could encompass various known DC subsets, most had an immature phenotype. We observed that TIDCs were able to present TAA in the context of major histocompatibility complex class I but that they were refractory to stimulation with the combination of lipopolysaccharide, interferon gamma, and anti-CD40 antibody. We could revert TIDC paralysis, however, by in vitro or in vivo stimulation with the combination of a CpG immunostimulatory sequence and an anti-interleukin 10 receptor (IL-10R) antibody. CpG or anti-IL-10R alone were inactive in TIDCs, whereas CpG triggered activation in normal DCs. In particular, CpG plus anti-IL-10R enhanced the TAA-specific immune response and triggered de novo IL-12 production. Subsequently, CpG plus anti-IL-10R treatment showed robust antitumor therapeutic activity exceeding by far that of CpG alone, and elicited antitumor immune memory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The therapeutic effect resulting from enhanced tumor-infiltrating DCs and macrophage infiltrate switching from M2 to M1 consequently produce increased IL-12 and tumor necrosis factor (TNF) (76).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intratumor injections of TLR9 ligand CpG and anti-IL10R antibody are able to reinforce antitumor efficacy in C26 and B16 animal models.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [76]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336 · cited 2×
“Although the main function of dendritic cells (DCs) * is probably to orchestrate a defense against pathogens, DCs are also well equipped to initiate antitumor responses (1).”
BackgroundA Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“We tested different combinations of substances with the aim of relieving tumor-mediated inhibition and simultaneously mediating DC activation, including combinations of the TLR-9 ligand CpG 1668 (21) and an anti–IL-10R blocking antibody (15).”
MethodMouse and human dendritic cell subtypes
Shortman, K., & Liu, Y.-J. (2002) · Nature Reviews Immunology · doi:10.1038/nri746 · Cited by 2,291 · cited 4×
“In contrast, TIDCs from X/myc hepatocarcinoma were representative of distinct subsets of mouse DCs (19).”
BackgroundResultInfluentialKadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R. A., Bazan, F., & Liu, Y.-J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.863 · Cited by 1,964 · cited 2×
“Furthermore, it will be of important to test whether our observations also apply to human tumor-infiltrating DCs. Interestingly, a population of plasmacytoid DC precursors has recently been described in human ovarian cancer (27) and these cells, in normal individuals, express TLR9 and respond to selected CpGs (28).”
BackgroundDhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.233 · Cited by 1,359 · cited 1×
“Indeed, it was recently reported that immature DC injection would induce antigen-specific T cell unresponsiveness in man (22).”
BackgroundMayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology
Asselin-Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter-Dambuyant, C., Vicari, A., O'Garra, A., Biron, C., Brière, F., et al. (2001) · Nature Immunology · doi:10.1038/ni736 · Cited by 1,022 · cited 1×
“On the other hand, TIDCs isolated from liver hepatocarcinoma were more diverse, including CD11b and CD11b DCs as well as cells expressing CD8 an/or B220, the latter marker being ascribed to mouse type I IFN-producing cells (19, 20).”
BackgroundSelf-citationZou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1339 · Cited by 653 · cited 1×
“Interestingly, a population of plasmacytoid DC precursors has recently been described in human ovarian cancer (27) and these cells, in normal individuals, express TLR9 and respond to selected CpGs (28).”
BackgroundBell, D., Chomarat, P., Broyles, D., Netto, G., Harb, G. M., Lebecque, S., Valladeau, J., Davoust, J., Palucka, K. A., & Banchereau, J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1417 · Cited by 544
Paglia, P., Chiodoni, C., Rodolfo, M., & Colombo, M. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.317 · Cited by 542
Self-citation
Cited by
Items 201–300 of 351
Innate immunity and cancer therapy
Maruyama, K., Selmani, Z., Ishii, H., & Yamaguchi, K. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.09.012 · Cited by 30
“In animal experiments, significant anti-tumor effects of TLR agonists have been demonstrated in a variety of settings not only in monotherapy [94,95] but also in combination therapy with monoclonal antibody therapy [96–102], cytokines, chemokines and related factors [103–106], TLR3 and TLR5 ligands [107,108], EGFR-rel…”
BackgroundRossowska, J., Anger, N., Szczygieł, A., Mierzejewska, J., & Pajtasz‐Piasecka, E. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0799-y · Cited by 29
Chen, S., Wang, X., Wu, X., Wei, M. Q., Zhang, B., Liu, X., & Wang, Y. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.06.002 · Cited by 28
Zhang, X., Munegowda, M. A., Yuan, J., Wei, Y. Z., & Xiang, J. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0909633 · Cited by 27
“[54] demonstrated originally a successful reversal of tolerogenic DCs by intratumoral injection of CpG plus anti-IL-10R antibody.”
BackgroundIFN-γ Negatively Regulates CpG-Induced IL-10 in Bone Marrow-Derived Dendritic Cells
Flores, R. R., Diggs, K. A., Tait, L. M., & Morel, P. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.211 · Cited by 33
CpG Oligodeoxynucleotides as Adjuvants for Clinical Use
Shirota, H., & Klinman, D. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804019-5.00009-8 · Cited by 28
Ciavarra, R. P., Holterman, D. A., Brown, R. R., Mangiotti, P., Yousefieh, N., Wright, G. L., Schellhammer, P. F., Glass, W. F., & Somers, K. D. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200401000-00002 · Cited by 26
“In addition, the TME can induce a state of paralysis, rendering DCs refractory to powerful maturation signals such as lipopolysaccharide and interferon- .(27) In view of these considerations, mice were treated with a combination of flt3-L and CD40-L to promote DC differentiation and augment the anti-tumor immune respo…”
BackgroundAntigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy
Wang, H. Y., & Wang, R. (2005) · Microbes and Infection · doi:10.1016/j.micinf.2005.03.028 · Cited by 26
Poth, J. M., Coch, C., Busch, N., Boehm, O., Schlee, M., Janke, M., Zillinger, T., Schildgen, O., Barchet, W., & Hartmann, G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001798 · Cited by 25
“However, within PBMCs, monocytes activated by TLR4 (LPS) or TLR2 (proteoglycans) released IL-10- and cyclooxygenase-dependent factors like PGs, which blocked responsiveness of PDCs to bacterial DNA or synthetic CpG DNA.”
ResultInfluentialThe Dendritic Cell Dilemma in the Skin: Between Tolerance and Immunity
Scheib, N., Tiemann, J., Becker, C., Probst, H. C., Raker, V., & Steinbrink, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929000 · Cited by 27
“However, melanoma-infiltrating DC also appear to become resistant to some maturation stimuli (49).”
BackgroundThe significance of cytokine-producing B cells in breast tumor-draining lymph nodes
Mehdipour, F., Razmkhah, M., Faghih, Z. S., Bagheri, M., Talei, A., & Ghaderi, A. A. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00433-3 · Cited by 25
Na, Y.-J., Jin, J., Lee, M., Song, M., Lee, K. S., & Kwak, J. (2007) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2007.03.013 · Cited by 28
Rossowska, J., Anger, N., Kicielińska, J., Pajtasz‐Piasecka, E., Bielawska‐Pohl, A., Wojas-Turek, J., & Duś, D. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.10.009 · Cited by 25
“It as been shown that elimination of IL-10 using IL-10/IL-10R antiodies (Vicari et al., 2002; Kalli et al., 2013), anti-IL-10 antisense ligonucleotides (Kim et al., 2000) or low-dose cyclophosphamide Matar et al., 2001) improved specific antitumour response against ertain tumour models.”
BackgroundPan, X., Ma, B., You, X., Chen, S., Wu, J., Wang, T., Walton, S. F., Yuan, J., Wu, X., Chen, G., et al. (2019) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-019-2571-z · Cited by 24
“Toll like receptor ligands, such as CpG and imiquimod, have also been used to break the immune suppressive microenvironment [21].”
MethodYotsumoto, S., Saegusa, K., & Aramaki, Y. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.809 · Cited by 24
“Treatment with anti-IL-10 receptor mAb plus CpGODN strikingly enhances antitumor activity compared with CpG-ODN alone (7, 9).”
BackgroundStewart, C. A., & Trinchieri, G. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.008 · Cited by 24
“…that TAMs and DCs can be driven to produce IL-12 with an antitumor effect by inhibiting IL-10 alone, suggesting that even if various factors induce STAT3 activation and expression in the tumor microenvironment, its antiinflammatory effect critically depends upon IL-10 (Vicari et al., 2002).”
BackgroundSelf-citationComparative analysis of cancer vaccine settings for the selection of an effective protocol in mice
Kalli, F., Machiorlatti, R., Battaglia, F., Parodi, A., Conteduca, G., Ferrera, F., Proietti, M., Tardito, S., Sanguineti, M., Millo, E., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-120 · Cited by 25
“Thus, the inhibition of IL-10 has been proposed as a useful strategy in anti-cancer therapy [25,26].”
BackgroundPotentiation of a Dendritic Cell Vaccine for Murine Renal Cell Carcinoma by CpG Oligonucleotides
Chagnon, F., Tanguay, S., Özdal, Ö. L., Guan, M., Özen, Z., Ripeau, J., Chevrette, M., ELHILALI, M. M., & Thompson-Snipes, L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1302.11.3 · Cited by 25
Plasmacytoid Dendritic Cells in Melanoma: Can We Revert Bad into Good?
Domizio, J. D., Demaria, O., & Gilliet, M. F. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.155 · Cited by 22
“Vicari et al. (2002) showed that only the combination of intratumoral CpG plus an anti-IL-10 antibody induced systemic T cell– mediated immunity capable of rejecting the tumors.”
BackgroundCancer Immunotherapy Using In vitro Genetically Modified Targeted Dendritic Cells
Wei, H., Wang, H., Lü, B., Li, B., Hou, S., Qian, W., Fan, K., Dai, J., Zhao, J., & Guo, Y. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6051 · Cited by 22
Perspectives on Reprograming Cancer-Associated Dendritic Cells for Anti-Tumor Therapies
Benencia, F., Muccioli, M., & Alnaeeli, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00072 · Cited by 23
“Upon treatment, the cells regain their ability to activate antigenspecific T cells (10, 49, 50).”
BackgroundStone, G. W., Barzee, S., Snarsky, V., Santucci, C., Tran, B., & Kornbluth, R. S. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a8634d · Cited by 21
Liu, Y. C., Gray, R. C., Hardy, G. A. D., Kuchtey, J., Abbott, D. W., Emancipator, S. N., & Harding, C. V. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903079 · Cited by 25
“ODNs were provided by Coley Pharmaceutical Group (Wellesley, MA), purchased from InvivoGen (San Diego, CA) or described elsewhere (21, 22), and synthesized by MWG-Biotech (High Point, NC).”
MethodFear, V. S., Poh, W. P., Valvis, S. M., Waithman, J. C., Foley, B. A., Wood, F. M., & Fear, M. W. (2016) · Burns · doi:10.1016/j.burns.2016.01.013 · Cited by 23
Llópiz, D., Aranda, F., Díaz‐Valdés, N., Ruiz, M., Infante, S., Belsúe, V., Lasarte, J. J., & Sarobe, P. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1075113 · Cited by 25
“2) or CpG.33 We thus studied the antitumor effect of IL10 blockade in conjunction with poly(I:C) and anti-CD40based vaccines, conditions where blockade of IL-10 does not result in enhanced T cell responses in naive mice.”
BackgroundMolecular Mechanism and Potential Targets for Blocking HPV-Induced Lesion Development
Guzmán-Olea, E., Bermúdez-Morales, V. H., Peralta-Zaragoza, Ó., Torres-Poveda, K., & Madrid‐Marina, V. (2011) · Journal of Oncology · doi:10.1155/2012/278312 · Cited by 21
Marchi, L. H. L., Paschoalin, T., Travassos, L. R., & Rodrigues, E. G. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.58 · Cited by 21
Ciavarra, R. P., Brown, R. R., Holterman, D. A., Garrett, M., Glass, W. F., Wright, G. L., Schellhammer, P. F., & Somers, K. D. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0383-x · Cited by 21
“Vicari and colleagues [39] also recently reported that solid tumors induce a state of DC paralysis that renders them refractory to stimulation with lipopolysaccharide, interferon-a and anti-CD40 mAb.”
BackgroundChemopreventive agents targeting tumor microenvironment
Sharma, S. H., Thulasingam, S., & Nagarajan, S. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.12.016 · Cited by 20
Triozzi, P. L., Aldrich, W. A., & Ponnazhagan, S. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.54 · Cited by 20
Novaković, S., Stegel, V., Kopitar, A. N., Ihan, A., & Novaković, B. J. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.09.067 · Cited by 23
Coukos, G., Conejo-Garcia, J. R., Buckanovich, R. J., & Benencia, F. (2007) · Springer eBooks · doi:10.1007/978-0-387-34814-8_13 · Cited by 23
Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine
Uchida, T. (2010) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2010.00273.x · Cited by 19
“It has been reported that CpG and the anti-IL10 receptor antibody reverse tumor-induced DC paralysis, resulting in tumor rejection by CTL activated by DC (37).”
BackgroundA TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine
Conforti, A., Cipriani, B., Peruzzi, D., Dharmapuri, S., Kandimalla, E. R., Agrawal, S., Mori, F., Ciliberto, G., Monica, N. L., & Aurisicchio, L. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.03.020 · Cited by 19
Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy
Tosch, C., Geist, M., Ledoux, C., Ziller-Remi, C., Paul, S., Erbs, P., Corvaïa, N., von Hoegen, P., Balloul, J.-M., & Haegel, H. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.85 · Cited by 21
A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy
Gupta, A. K., Nuber, N., Esslinger, C., Wittenbrink, M., Treder, M., Landshammer, A., Noguchi, T., Kelly, M. P., Gnjatic, S., Ritter, E., et al. (2013) · Europe PMC (PubMed Central) · doi:10.5167/uzh-81963 · Cited by 19
Cure of Chronic Viral Infection and Virus‐Induced Type 1 Diabetes by Neutralizing Antibodies
Ejrnaes, M., von Herrath, M. G., & Christen, U. (2006) · Journal of Immunology Research · doi:10.1080/17402520600800721 · Cited by 19
“Moreover, treatment with a combination of anti-IL-10 receptor (IL-10R) monoclonal antibody (mAb) and toll-like receptor 9 (TLR9) ligands has been shown to have potent therapeutic anti-tumor effects (Vicari et al. 2002; Vicari and Trinchieri 2004), pointing to the role of IL10 in the development of cancer.”
BackgroundDu, Y., Lin, P., Zhang, J., Lu, Y. ‐., Ning, Q., & Wang, Q. (2006) · Tissue Antigens · doi:10.1111/j.1399-0039.2006.00590.x · Cited by 19
Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors
Kalkusova, K., Smite, S., Darras, E., Táborská, P., Stakheev, D., Vannucci, L. E., Bartůňková, J., & Smrž, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911080 · Cited by 19
“Restoration of efficient antitumor activity of otherwise defective tumor-infiltrating DCs was already demonstrated for many tumors using different approaches [98,161,162].”
The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors
Scheuerpflug, A., Ahmetlić, F., Bauer, V., Riedel, T., Röcken, M., & Mocikat, R. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02767-6 · Cited by 21
“Thus, in some endogenous mouse tumor models, DCs displayed a downregulation of costimulatory molecules [23, 30], whereas a mature phenotype was observed in other neoplasias including the λ-MYC lymphoma [24, 31].”
BackgroundChen, D., Zhang, X., Du, Y., Jia, B., Ka, W., Sun, D., Yao, W., & Wen, Z. (2011) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-011-9282-5 · Cited by 17
“The combination of anti-IL-10 antibody and CpG, an immunostimulatory oligonucleotide, as well as anti-IL-10R antibody and CpG, is superior to CpG alone for restoring DC functions in tumor condition [31–33].”
BackgroundLi, G., WU, K., Tao, K., Lu, X., Jianhua, M., Mao, Z., Li, H., Shi, L., LI, J., Niu, Y., et al. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3374 · Cited by 17
“Dendritic cells (DCs) are a type of effective immune cell and it has been confirmed that anti‑inflammatory IL‑10 interferes with DC maturation (42).”
Ni, G., Chen, S., Yang, Y., Cummins, S. F., Zhan, J., Li, Z., Zhu, B., Mounsey, K. E., Walton, S. F., Wei, M. Q., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153939 · Cited by 16
“In vivo inhibition of IL-10 signalling can be achieved through administration of anti-IL-10R antibodies [15, 16].”
BackgroundHuang, C.-H., Chang, C., Lin, C.-M., Wang, S.-T., Wu, M.-T., Li, E. I. C., Chang, H., & Lin, C. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0852-y · Cited by 15
Role of dendritic cells in the regulation of antitumor immunity
Wathelet, N., & Moser, M. (2013) · OncoImmunology · doi:10.4161/onci.23973 · Cited by 15
“Early evidence in support of this notion was provided in 2002 by Vicari and colleagues, who observed that DCs infiltrating transplantable tumors and hepatocarcinomas developing in X/myc transgenic mice essentially displayed an immature phenotype.(21) Moreover, these immature DCs were refractory to lipopolysaccharide (…”
ResultAre Macrophages in Tumors Good Targets for Novel Therapeutic Approaches?
Alahari, S. V., Dong, S., & Alahari, S. K. (2014) · Molecules and Cells · doi:10.14348/molcells.2015.2298 · Cited by 16
“This was attempted by using the CpG immunostimulatory oligonucleotide and anti-IL10 receptor which caused macrophages to turn from M2 to M1 (Vicari et al., 2002).”
Immunothérapie des cancers par oligonucléotides immunostimulants
Carpentier, A. F. (2005) · médecine/sciences · doi:10.1051/medsci/200521173 · Cited by 14
“Dans un modèle animal, la combinaison de CpG et d’anticorps anti-IL-10 a d’ailleurs révélé l’existence d’un effet synergique [25].”
Shilyansky, J., Jacobs, P., Doffek, K. M., & Sugg, S. L. (2007) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2006.09.008 · Cited by 14
Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides
Brignole, C., Marimpietri, D., Pastorino, F., Paolo, D. D., Pagnan, G., Loi, M., Piccardi, F., Cilli, M., Tradori-Cappai, A., Arrigoni, G., et al. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.05.006 · Cited by 13
Jackson, S. R., Berrien-Elliott, M. M., Meyer, J. M., Wherry, E. J., & Teague, R. M. (2013) · Immunological Investigations · doi:10.3109/08820139.2012.751397 · Cited by 16
“, 1992), and thus, similar therapeutic approaches have proven beneficial in these distinct environments (Ercolini et al., 2005; Martin-Orozco et al., 2006; Probst et al., 2005; Vicari et al., 2002; Zhang et al., 2005).”
InfluentialWang, F., Wang, Y. Y., Li, J., You, X., Qiu, X. H., Wang, Y. N., & GAO, F. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105636 · Cited by 12
“Apart from IFN-I, we also mentioned the overlapping roles of IL-10 and IFN-I in impairing CTL immunity of sepsis patients [13,14,27].”
BackgroundNi, G., Liao, Z., Chen, S., Wang, T., Yuan, J., Pan, X., Mounsey, K. E., Walton, S. F., Liu, X., & Wei, M. Q. (2017) · BMC Immunology · doi:10.1186/s12865-017-0224-x · Cited by 12
“receptor antibody intraperitoneally, leads to tumour rejection in mouse tumour models [47].”
Adhesion to substrates induces dendritic cell endothelization and decreases immunological response
Osterbur, J., Sprague, L., Muccioli, M., Pate, M., Mansfield, K., McGinty, J. W., Li, Y., Li, Y., Shirure, V. S., Courreges, M. C., et al. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.02.003 · Cited by 13
“To accomplish this we used LPS or a combination of CPG plus anti-IL10 receptor, which has been shown to overcome the immune paralysis of tumor-associated DCs (13).”
BackgroundMethodNaujoks, M., Weiß, J. V., Riedel, T., Hömberg, N., Przewoznik, M., Noeßner, E., Röcken, M., & Mocikat, R. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1538-7 · Cited by 11
Nunes, F. P. B., Alberca, R. W., Gomes, E., da Fonseca, D. M., Yokoyama, N. H., Labrada, A., & Russo, M. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.ma1218-475rr · Cited by 11
The effects of indoprofen vs paracetamol on swelling, pain and other events after surgery.
Olstad, O. A., & Skjelbred, P. (1986) · PubMed · Cited by 13
The show and tell of cross-presentation
Blander, J. M., Mon, K. J. Y., Jha, A., & Roycroft, D. (2023) · Advances in immunology · doi:10.1016/bs.ai.2023.08.002 · Cited by 10
Cure of chronic viral infection by neutralizing antibody treatment
Ejrnaes, M., & von Herrath, M. G. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2006.09.002 · Cited by 9
(2012) · Journal of Cell Science & Therapy · doi:10.4172/2157-7013.1000134 · Cited by 9
“Indeed, tumour-associated DCs are usually described as immature cells with low expression of co-stimulatory molecules and incapable of inducing robust anti-tumour immune responses [3-7].”
BackgroundHira, S. K., & Manna, P. P. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.02.015 · Cited by 9
Targeting the dendritic cell: the key to immunotherapy in cancer?
Faith, A., & Hawrylowicz, C. M. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02737.x · Cited by 9
Nutrition, Immunity, and Cancer
Ghaedi, E., Rezaei, N., & Mahmoudi, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-16073-9_12 · Cited by 9
Role of Monocyte-Derived Dendritic Cells (MoDCs) in Tumor Immune Response
Pourahmad, R., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_20-1 · Cited by 11
Inflammatory and Innate Immune Cells in Cancer Microenvironment and Progression
Brennecke, P., Allavena, P., Laface, I., Mantovani, A., & Bottazzi, B. (2014) · Springer eBooks · doi:10.1007/978-3-662-44006-3_2 · Cited by 10
Ma, Y., Bauer, V., Riedel, T., Ahmetlić, F., Hömberg, N., Höfer, T., Röcken, M., & Mocikat, R. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.01.022 · Cited by 10
Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma
Yu, S. J., & Greten, T. F. (2020) · Journal of Liver Cancer · doi:10.17998/jlc.20.1.1 · Cited by 8
Trad, M., Gautheron, A., Fraszczak, J., Alizadeh, D., Larmonier, C. B., LaCasse, C. J., Centuori, S. M., Audia, S., Samson, M., Ciudad, M., et al. (2015) · BioMed Research International · doi:10.1155/2015/891236 · Cited by 8
Regulating the regulators via targeting CD38 in the tumor microenvironment
Dutta, N., Halder, N., Chini, E. N., Kim, S., & Manna, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1745988 · Cited by 9
No immunosurveillance in human IL-10R deficiency
Oft, M. (2013) · Blood · doi:10.1182/blood-2013-10-531657 · Cited by 7
“In addition, as reported recently in another study, Trim28 mutant red cells failed to activate mitophagy-associated genes.(7)”
BackgroundResultEjrnaes, M., von Herrath, M. G., & Christen, U. (2006) · Journal of Immunology Research · doi:10.1080/17402520600579028 · Cited by 7
RetractedMiller, C. L., Sagiv-Barfi, I., Neuhöfer, P., Czerwinski, D. K., Bertozzi, C. R., Cochran, J. R., & Levy, R. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200950 · Cited by 6
Węgierek‐Ciura, K., Mierzejewska, J., Szczygieł, A., Rossowska, J., Wróblewska, A., Świtalska, M., Goszczyński, T. M., Szermer-Olearnik, B., & Pajtasz‐Piasecka, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212606 · Cited by 6
“For this purpose, we used antibodies directed against the IL-10R receptor, which should partially block the negative effect of IL-10 on the cells of the immune system (23, 42) and HES-MTX as an immunomodulatory chemotherapeutic agent.”
MethodKamperschroer, C., Goldstein, R., Schneider, P. A., Kuang, B., & Eisenbraun, M. D. (2019) · Journal of Immunotoxicology · doi:10.1080/1547691x.2019.1656683 · Cited by 6
“(Brooks et al. 2006) and cancer (Vicari et al. 2002; Guiducci et al. 2005; Newton et al. 2014).”
Elizondo, C. R., Bright, J. D., Byrne, J. A., & Bright, R. K. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1689746 · Cited by 6
“have shown that administration of CpG immunostimulatory oligonucleotide in conjunction with anti-IL-10 receptor antibody elicited robust antitumor therapeutic responses marked by anti-tumor immune memory in a mouse treatment model of pre-established tumors.(42) Similarly, our model employs the use of a molecular adjuv…”
MethodFu, J., Chen, J., Ni, J., Liu, X., Yao, Q., Shou, Q., & Fu, H. (2025) · Food & Function · doi:10.1039/d5fo01116g · Cited by 5
Repáraz, D., Ruiz, M., Silva, L., Aparicio, B., Egea, J., Guruceaga, E., Ajona, D., Senent, Y., Conde, E., Navarro, F. C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991311 · Cited by 5
Efficacy of Using Dendritic Cells in the Treatment of Prostate Cancer: A Systematic Review
Pacheco, H. F. M., Fernandes, J. L. F., Dias, F. C. R., Deus, M. C., Ribeiro, D. L., Michelin, M. A., & Gomes, M. D. L. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104939 · Cited by 4
The Basis of Anticancer Immunity Mechanism Induced by In Situ Vaccination
Proskurina, A. S., Ruzanova, V. S., Викторовна, Т. Т., Николаевич, С. Д., Kirikovich, S. S., Ritter, G. S., Efremov, Y. R., & Bogachev, S. S. (2020) · Journal of Siberian Federal University Biology · doi:10.17516/1997-1389-0326 · Cited by 4
Zhang, X., Moyana, T. N., Quereshi, M., & Xiang, J. (2006) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2006.21.74 · Cited by 4
Lin, P., Lu, Y., Zhang, J., Wei, Y.-Q., Wang, X., Li, S., Wang, Q., Xiong, Z., Ning, Q., Lei, S., et al. (2008) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0463 · Cited by 4
Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma
Friedberg, J. W., & Freedman, A. S. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0037-2 · Cited by 4
“CpG sequences have been shown to have potential direct antitumor effects in murine models [34] and have been shown in animal models to enhance antitumor immunizations with and without classical adjuvants [35, 36 ].”
BackgroundModulation of Tumor Microenvironment via Antibody Mediated Precision Delivery of CpG to Myeloid Cell
Xiang, Y., Hao, X., Li, H., Ma, Z., Ma, Z., Ji, L., Yang, Z., Wang, J., Chen, M., & Baigude, H. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03629 · Cited by 3
Arab, S., Mojarrad, M., Motamedi, M., Mirzaei, R., Modarressi, M. H., & Hadjati, J. (2013) · Scandinavian Journal of Immunology · doi:10.1111/sji.12058 · Cited by 3
Retinoic acid on stage in antitumor immunity
Guo, Y., & Noelle, R. J. (2013) · OncoImmunology · doi:10.4161/onci.22985 · Cited by 3
The surprising role of IL-10 as a potent inducer of IFN-g-mediated CD8 þ T cell cytotoxicity
Mumm, J. B., & Oft, M. (2013) · Cited by 3
The role of microbiota and immune system crosstalk in cancer development and therapy
Behrouzi, A., Katebi, A., Riazi‐Rad, F., Mazaheri, H., & Ajdary, S. (2022) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2022.01650 · Cited by 3
“In mice, all myeloid cells express TLR9, intra-tumoral injection of CpG-ODN alone, or especially with anti-IL-10 receptor antibodies, which enhance the TSA-specific immune response and are effective against tumors [50].”
BackgroundNi, G., Wang, T., Yang, L., Wang, Y., Liu, X., & Wei, M. Q. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1089008 · Cited by 4
“It is accepted that tumor associated dendritic cells are deficient at present tumor associated antigen (TAA) to T cells.(38,39)”
BackgroundKontani, K., Teramoto, K., Ozaki, Y., Sawai, S., Tezuka, N., Ishida, H., Kajino, K., Fujino, S., Yamauchi, A., Taguchi, O., et al. (2007) · Oncology Reports · doi:10.3892/or.17.4.895 · Cited by 3
“Indeed, immature DCs and tumor-infiltrated DCs have been shown to be tolerogenic (44,45).”
Xiang, X., Zhou, X.-Q., Wang, J.-X., Xie, Q., Cai, X., Yu, H., & Zhou, H.-J. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i43.4825 · Cited by 3
Aptamers as a Promising Therapeutic Tool for Cancer Immunotherapy
Soldevilla, M. M., Villanueva, H., & Pastor, F. (2017) · InTech eBooks · doi:10.5772/66964 · Cited by 3
“The blockade of its receptor IL-10R has been described to inhibit tumor growth in murine tumor models [67, 68].”
BackgroundTHE ROLE OF INTERLEUKIN-10 IN HELICOBACTER PYLORI INFECTION.
Zakaria, Z. (2010) · Nottingham ePrints (University of Nottingham) · Cited by 4
Genome DNA methylation, aneuploidy and immunity in cancer.
Veronese, A. (2020) · Epigenomics · doi:10.2217/epi-2020-0051 · Cited by 3
Kalkusova, K., Táborská, P., Stakheev, D., Rataj, M., Smite, S., Darras, E., Albo, J., Bartůňková, J., Vannucci, L. E., & Smrž, D. (2024) · Journal of Immunology Research · doi:10.1155/2024/5537948 · Cited by 2
“Under many disease conditions, namely in tumors, the specimen in fi ltration with DCs with immature phenotype is often associated with immunosuppression or impaired immunostimulatory activities [59, 60, 61, 62, 63].”
BackgroundThe role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review
Štajer, M., Horáček, J. M., Kupsa, T., & Зак, П. (2024) · Journal of Applied Biomedicine · doi:10.32725/jab.2024.024 · Cited by 2
Cancer immunotherapy via nucleic acid aptamers
Zahedipour, F., Majeed, M. A., Kesharwani, P., & Sahebkar, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85881-6.00003-8 · Cited by 2
T cell immunity against early antigens of Human Papillomavirus type 16
de Jong, A. (2005) · Cited by 2
Malfunction of the Dendritic Cell System in Cancer
Yurkovetsky, Z. R., Tourkova, I. L., Balkir, L., Perez, L., Shurin, G. V., Chatta, G. S., & Shurin, M. R. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-743-7_3 · Cited by 2
Nanotechnology-Based Immunotherapeutic Strategies for the Treatment of Cancer
Sharma, R. K., Mody, N., & Vyas, S. P. (2017) · Springer eBooks · doi:10.1007/978-981-10-3647-7_3 · Cited by 3
Chang, J., Zhang, W., Lin, G.-Y., Tong, D., Zhu, D. Y., Zhao, J., Yu, Q., Huang, D., & Li, W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s275636 · Cited by 2
Tian, H., Shi, G., Yang, G., Zhang, J., Li, Y., Du, T., Wang, J., Xu, F., Cheng, L., Zhang, X., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-6544-x · Cited by 2
Metadata
- Authors
- Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., O'Garra, A., Trinchieri, G., & Caux, C.
- Affiliations
- 1Schering-Plough Laboratory for Immunological Research, 69571 Dardilly, France
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Inserm (FR)
- 4DNAX Research Institute, Palo Alto, CA 94304
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2002-08-19
- Volume
- 196
- Issue
- 4
- Pages
- 541-549
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2196048
- OpenAlex
- W2156592930
- Cited by
- 343
- References
- 35
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 8 · 2020: 8 · 2019: 14 · 2018: 7 · 2017: 19 · 2016: 12 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 21
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-infiltrating dendritic cells, MHC class I, DC maturation, IL-12, antitumor immunity, antitumor immune memory, transplantable tumors
- MeSH terms
- Adjuvants, Immunologic, Animals, Antibodies, Monoclonal, Dendritic Cells, Female, Immunity, Active, Immunity, Innate, Immunologic Memory, Interferon-gamma, Killer Cells, Natural, Lipopolysaccharides, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Oligodeoxyribonucleotides, Tumor Cells, Cultured, Antigens, Tumor-Associated, Carbohydrate, Mice, SCID, Receptors, Interleukin, CD8-Positive T-Lymphocytes, CpG Islands, CD40 Antigens, Mice, Receptors, Interleukin-10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.